Press release
Ulcerative Colitis Therapeutics Market to Reach USD 11.9 Billion by 2035, Growing at a CAGR of 5.1% Amid Rising Prevalence and Advancements in Treatment Options
The global ulcerative colitis therapeutics market is valued at USD 7.2 billion in 2025. As per Fact.MR analysis, the industry will grow at a CAGR of 5.1% and will reach USD 11.9 billion by 2035. according to Fact.MR's comprehensive analysis. The increasing prevalence of ulcerative colitis, a chronic inflammatory bowel disease causing inflammation and ulceration in the large bowel , is a primary driver of market growth. Rising awareness of the condition, advancements in diagnostic technologies, and the growing adoption of biologics and targeted therapies are further fueling the market's expansion. The focus on personalized medicine and the integration of artificial intelligence (AI) in drug development and disease management are also enhancing treatment efficacy, positioning the market for steady growth over the forecast period.The demand for ulcerative colitis therapeutics is driven by the increasing incidence of inflammatory bowel diseases globally, coupled with innovations in biologics, such as JAK inhibitors and monoclonal antibodies. These therapies offer improved outcomes for patients with moderate to severe ulcerative colitis, contributing to market growth. Additionally, enhanced diagnostic capabilities and rising patient education are encouraging early diagnosis and treatment, further boosting demand. The market is also benefiting from strategic partnerships, mergers, and acquisitions, which are expanding access to innovative treatments and strengthening global distribution networks.
Ulcerative colitis therapeutics are used across various disease types, including ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis, and fulminant colitis. Pancolitis, or universal colitis, is the most profitable segment due to its severity and reliance on costly biologics and immunosuppressants, with an estimated CAGR of 5.5% through 2035. By route of administration, injectables, particularly biologics and monoclonal antibodies, are experiencing faster uptake due to their higher efficacy and longer remission periods, with a projected CAGR of 5.6%. Oral treatments, such as aminosalicylates and corticosteroids, remain widely used for mild to moderate cases due to their ease of use and patient preference.
Browse Full Report: https://www.factmr.com/report/ulcerative-colitis-therapeutics-market
"Innovation in biologics and precision medicine is transforming ulcerative colitis treatment, improving patient outcomes and driving market growth. Companies must prioritize R&D investments and strategic partnerships to stay competitive in this rapidly evolving landscape," opines a Fact.MR analyst.
Ulcerative Colitis Therapeutics Market Insights: Key Trends and Growth
The Fact.MR report underscores robust market growth driven by the rising prevalence of ulcerative colitis, advancements in therapeutic options, and increasing adoption of biosimilars. Key trends include the growing use of JAK inhibitors and monoclonal antibodies for aggressive disease management and the integration of AI-powered diagnostics for personalized treatment. North America and Europe dominate the market due to advanced healthcare infrastructure and high disease prevalence, while the Asia-Pacific region, particularly India and China, is witnessing rapid growth due to improving healthcare systems and rising awareness. However, challenges such as regulatory barriers, competition from biosimilars, and supply chain disruptions pose risks to market expansion.
Key Takeaways from the Market Study
-The global ulcerative colitis therapeutics market is expected to grow at a CAGR of 5.1% from 2025 to 2035, reaching USD 11.9 billion.
-North America leads the market, with the United States projected to grow at a CAGR of 5.3% through 2035, driven by high R&D expenditure and biologics uptake.
-The Asia-Pacific region, led by India (CAGR 5.6%) and China (CAGR 5.4%), is emerging as a high-growth market due to increasing healthcare investments.
-Pancolitis is the most lucrative disease type segment, with a CAGR of 5.5%, driven by demand for advanced biologics.
-Injectables are the fastest-growing route of administration, with a CAGR of 5.6%, due to their efficacy in severe cases.
-Biosimilars are gaining traction, particularly in Europe (84% stakeholder focus), to address affordability concerns.
Ulcerative Colitis Therapeutics Market Competitive Landscape
The ulcerative colitis therapeutics market is moderately consolidated, with key players like AbbVie, Johnson & Johnson (Janssen), Takeda Pharmaceutical, Pfizer, and Bristol-Myers Squibb dominating through innovation and strategic collaborations. AbbVie holds the largest market share (35-40%) with drugs like Humira, Rinvoq, and Skyrizi, followed by Janssen (20-25%) with Stelara and Takeda (15-20%) with Entyvio. Recent developments include AbbVie's acquisition of Landos Biopharma in March 2024 for USD 137 million to bolster its inflammatory bowel disease portfolio and Teva Pharmaceuticals' promising Phase 2b trial results for duvakitug in December 2024. The European Medicines Agency's endorsement of ustekinumab biosimilars, such as Yesintek, in December 2024 further intensifies competition. Companies are focusing on next-generation biologics, AI-driven diagnostics, and global expansion to maintain market leadership.
Ulcerative Colitis Therapeutics Market Key Companies Profiled
AbbVie
Takeda Pharmaceutical
Pfizer
Bristol-Myers Squibb
Roche/Genentech
Amgen
AstraZeneca
Eli Lilly
Merck & Co.
Gilead Sciences
Cosmo Pharmaceuticals
Astellas Pharma
BioLineRx
Landos Biopharma
Celltrion
For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7286
Ulcerative Colitis Therapeutics Industry News
-In March 2024, AbbVie acquired Landos Biopharma to expand its ulcerative colitis portfolio with NX-13, an oral drug candidate.
-In December 2024, Teva Pharmaceuticals and Sanofi reported positive Phase 2b trial results for duvakitug, advancing to Phase 3 trials.
-In December 2024, the European Medicines Agency endorsed ustekinumab biosimilars for ulcerative colitis treatment, enhancing affordability.
Explore More Related Studies Published by Fact.MR Research
Zero Speed Switch Market : https://www.factmr.com/report/zero-speed-switch-market
Insulated Styrofoam Shipping Boxes Market : https://www.factmr.com/report/insulated-styrofoam-shipping-boxes-market
Insulated Drum Covers Market : https://www.factmr.com/report/insulated-drum-covers-market
Parenteral Drugs Packaging Market :https://www.factmr.com/report/parenteral-drugs-packaging-market
Intravenous Packaging Market https://www.factmr.com/report/intravenous-packaging-market
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com
About Fact.MR
Fact.MR is a trusted market research partner for 80% of Fortune 1000 companies globally, delivering over 1000 reports annually. With a dedicated team of 400+ analysts and consultants, Fact.MR provides actionable insights to drive client satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ulcerative Colitis Therapeutics Market to Reach USD 11.9 Billion by 2035, Growing at a CAGR of 5.1% Amid Rising Prevalence and Advancements in Treatment Options here
News-ID: 4120928 • Views: …
More Releases from FactMR

Trail Running Shoes Market to Reach USD 14.1 Billion by 2033 | Nike, Adidas, Sal …
The global trail running shoes market size has reached a valuation of US$ 8.05 Billion in 2023, and is projected to reach US$ 14.10 Billion by 2033, forecasted to expand at a steady compound annual growth rate (CAGR) of 5.7% during the forecast period from 2023 to 2032.
according to a comprehensive report by Fact.MR. This growth is fueled by the rising popularity of adventure sports, increasing participation in trail running…

Shoe Deodorizer Market to Reach USD 470 Million by 2033 | Arm & Hammer, Dr. Scho …
Expanding at 5.6% CAGR from 2023 to 2033, the global shoe deodorizer market is expected to increase from a size of US$ 272 million in 2023 to US$ 470 million by the end of 2033.
. This growth is fueled by increasing consumer awareness of personal hygiene, rising participation in outdoor and athletic activities, and the growing demand for specialized shoe care products. The market is driven by evolving consumer preferences,…

Plastic Furniture Market to Reach USD 26.7 Billion by 2033 | Keter Group, Tramon …
Worldwide sales of plastic furniture are estimated at US$ 15.05 billion for 2023 and are forecasted to jump to US$ 26.7 billion by the end of 2033. Over the next ten years, the global plastic furniture market is predicted to expand at a steady 5.9% CAGR.
This growth is driven by increasing demand for lightweight, affordable, and sustainable furniture solutions, particularly in residential applications, fueled by global urbanization and rising consumer…

Dental Anesthetics Market to Reach USD 1.81 Billion by 2033 | Septodont, Dentspl …
The global dental anesthetics market, as detailed in the study by Fact.MR, reached a value of US$ 1.01 billion in 2022. Worldwide demand for dental anesthetics is predicted to increase at a CAGR of 5.4% and climb to a market valuation of US$ 1.81 billion by 2033-end.
This growth is driven by increasing demand for dental procedures, rising prevalence of dental disorders, and advancements in anesthetic formulations. The market is benefiting…
More Releases for CAGR
[CAGR of 6.7%] Nanocoatings Market Size, Industry Share, CAGR, Regional Forecast …
The global Nanocoatings Market generated $10.7 billion in 2020, and is projected to reach $20.1 billion by 2030, growing at a CAGR of 6.7% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and wavering market trends.
Download sample PDF @ https://www.alliedmarketresearch.com/request-sample/2064
According to the report published by Allied Market Research,…
[CAGR of 5.3%] Pigments Market Size, Industry Share, CAGR, Regional Forecast, 20 …
A recent report by Allied Market Research provides a detailed analysis of the pigments market, highlighting its robust growth. The industry was valued at $27.2 billion in 2022 and is projected to surge to $45.4 billion by 2032, exhibiting an impressive CAGR of 5.3% from 2023 to 2032.
This research report identifies the growth drivers behind the market's expansion and delves into the market dynamics using advanced analytical frameworks…
[CAGR of 5.5%] Silica Flour Market Size, CAGR, Competitive Analysis and Forecast …
The global silica flour industry generated $520.0 million in 2021, and is estimated to reach $876.3 million by 2031, witnessing a CAGR of 5.5% from 2022 to 2031.
Allied Market Research published a report, titled, "Silica Flour Market by Type (Quartz, Cristobalite), by Application (Fiberglass, Glass and Clay, Oil Well Cement, Ceramic and Refractory, Foundry, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." The report offers a detailed analysis…
Enzymes Market Expansion CAGR of 4.9% CAGR Anticipated 2025-2034
The Enzymes Market report is an in-depth examination of the global Enzymes Market's general consumption structure, development trends, sales techniques, and top nations' sales. The research looks at well-known providers in the global Enzymes Market industry, as well as market segmentation, competition, and the macroeconomic climate. A complete Enzymes Market analysis takes into account a number of aspects, including a country's population and business cycles, as well as market-specific microeconomic…
Electric Bed Market CAGR, Size, Share Grow USD 2,063 Million by 2030 CAGR 13.70%
Global electric bed market size is expected to be worth roughly USD 2,063 million by 2030, growing at a CAGR of more than 13.7% during the projected timeframe of 2022-2030, according to Ameco Research
A significant portion of the population over the age of 60, who often have reduced immunity levels and are more susceptible to neurological disorders, cardiac issues, tumors, and spinal cord compression, is anticipated to have a substantial…
Call Center AI Market Latest, CAGR, Volume and Value 2022-2030 | (CAGR) of 25%
New York , United States- Report Ocean published the latest research report on the Call Center AI market. In order to comprehend a market holistically, a variety of factors must be evaluated, including demographics, business cycles, and microeconomic requirements that pertain precisely to the market under study. In addition, the Call Center AI market study demonstrates a detailed examination of the business state, which represents creative ways for company growth,…